Transplantační medicína

PRALUENT: a PCSK9i that ticks all the boxes^1–4 PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.² It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.² Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.¹

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.

Obejrzysz w 60 minut

Systematic review shows Beyfortus^® reduces RSV hospitalizations by 83% and ICU admissions by 81% in real-world infant immunization programs.

Systematic review shows Beyfortus^® reduces RSV hospitalizations by 83% and ICU admissions by 81% in real-world infant immunization programs.